Specifically, overexpression of MASTL has been linked with tumor progression and poor outcomes in breast (Álvarez-Fernández et al., 2018; Rogers et al., 2018; Yoon et al., 2018), oral (Wang et al., 2014), gastric (Sun et al., 2017) and colon cancer (Vera et al., 2015; Uppada et al., 2018). Here, MASTL is linked to neoplasm.